JP2011501675A - Ｓｄｆ−１を基礎としたグリコサミノグリカンアンタゴニスト、及びその使用方法 - Google Patents
Ｓｄｆ−１を基礎としたグリコサミノグリカンアンタゴニスト、及びその使用方法 Download PDFInfo
- Publication number
- JP2011501675A JP2011501675A JP2010530341A JP2010530341A JP2011501675A JP 2011501675 A JP2011501675 A JP 2011501675A JP 2010530341 A JP2010530341 A JP 2010530341A JP 2010530341 A JP2010530341 A JP 2010530341A JP 2011501675 A JP2011501675 A JP 2011501675A
- Authority
- JP
- Japan
- Prior art keywords
- sdf
- protein
- mutant protein
- amino acid
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 15
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 title claims description 74
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 title claims description 67
- 229920002683 Glycosaminoglycan Polymers 0.000 title abstract description 62
- 239000005557 antagonist Substances 0.000 title description 4
- 230000001965 increasing effect Effects 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 claims abstract description 11
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims abstract description 9
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims abstract description 9
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 9
- 201000011510 cancer Diseases 0.000 claims abstract description 9
- 150000001413 amino acids Chemical class 0.000 claims description 49
- 102000008300 Mutant Proteins Human genes 0.000 claims description 28
- 108010021466 Mutant Proteins Proteins 0.000 claims description 28
- 210000004027 cell Anatomy 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 239000013598 vector Substances 0.000 claims description 15
- 238000006467 substitution reaction Methods 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 7
- 238000012217 deletion Methods 0.000 claims description 7
- 238000012986 modification Methods 0.000 claims description 7
- 230000004048 modification Effects 0.000 claims description 7
- 238000003776 cleavage reaction Methods 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 230000007017 scission Effects 0.000 claims description 6
- 108020004414 DNA Proteins 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 210000004897 n-terminal region Anatomy 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 5
- 102000040430 polynucleotide Human genes 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 238000000978 circular dichroism spectroscopy Methods 0.000 claims description 4
- 238000012423 maintenance Methods 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- 102000053602 DNA Human genes 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 210000002536 stromal cell Anatomy 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 235000001014 amino acid Nutrition 0.000 description 37
- 235000018102 proteins Nutrition 0.000 description 20
- 102000019034 Chemokines Human genes 0.000 description 19
- 108010012236 Chemokines Proteins 0.000 description 19
- 229920002971 Heparan sulfate Polymers 0.000 description 13
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 11
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 11
- 108010061299 CXCR4 Receptors Proteins 0.000 description 9
- 102000012000 CXCR4 Receptors Human genes 0.000 description 9
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
- 239000000539 dimer Substances 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 102000001902 CC Chemokines Human genes 0.000 description 3
- 108010040471 CC Chemokines Proteins 0.000 description 3
- 108050006947 CXC Chemokine Proteins 0.000 description 3
- 102000019388 CXC chemokine Human genes 0.000 description 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 102000023732 binding proteins Human genes 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 230000035605 chemotaxis Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 229920000045 Dermatan sulfate Polymers 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 2
- 229940051593 dermatan sulfate Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 101150079978 AGRN gene Proteins 0.000 description 1
- 102100040026 Agrin Human genes 0.000 description 1
- 108700019743 Agrin Proteins 0.000 description 1
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 241000342651 Capila Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100020997 Fractalkine Human genes 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- 102000010956 Glypican Human genes 0.000 description 1
- 108050001154 Glypican Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102100035304 Lymphotactin Human genes 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 102000019361 Syndecan Human genes 0.000 description 1
- 108050006774 Syndecan Proteins 0.000 description 1
- 102100035721 Syndecan-1 Human genes 0.000 description 1
- 108090000058 Syndecan-1 Proteins 0.000 description 1
- 102000003711 Syndecan-2 Human genes 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 102100037220 Syndecan-4 Human genes 0.000 description 1
- 108010055215 Syndecan-4 Proteins 0.000 description 1
- 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 125000003295 alanine group Chemical class N[C@@H](C)C(=O)* 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 108010079292 betaglycan Proteins 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 102000043525 human CXCL12 Human genes 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 108010019677 lymphotactin Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000000238 one-dimensional nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 108010049224 perlecan Proteins 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07450189A EP2053060A1 (en) | 2007-10-24 | 2007-10-24 | SDF-1-based glyocosaminoglycan antagonists and methods of using same |
| PCT/EP2008/008960 WO2009053064A1 (en) | 2007-10-24 | 2008-10-23 | Sdf-1-based glycosaminoglycan antagonists and methods of using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011501675A true JP2011501675A (ja) | 2011-01-13 |
| JP2011501675A5 JP2011501675A5 (enExample) | 2013-11-07 |
Family
ID=39133777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530341A Pending JP2011501675A (ja) | 2007-10-24 | 2008-10-23 | Ｓｄｆ−１を基礎としたグリコサミノグリカンアンタゴニスト、及びその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100298203A1 (enExample) |
| EP (2) | EP2053060A1 (enExample) |
| JP (1) | JP2011501675A (enExample) |
| KR (1) | KR20100085041A (enExample) |
| CN (1) | CN101835800A (enExample) |
| AU (1) | AU2008315614A1 (enExample) |
| BR (1) | BRPI0818009A2 (enExample) |
| CA (1) | CA2702502A1 (enExample) |
| EA (1) | EA201000688A1 (enExample) |
| IL (1) | IL205300A0 (enExample) |
| MX (1) | MX2010004025A (enExample) |
| NZ (1) | NZ584278A (enExample) |
| WO (1) | WO2009053064A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201200470A1 (ru) * | 2009-09-11 | 2012-08-30 | Протаффин Биотехнологие Аг | Композиция для лечения опосредуемого cxcl8 воспаления легкого |
| CN102094043B (zh) * | 2010-11-23 | 2012-11-07 | 山东农业大学 | 猪趋化因子cxcl12基因及其应用 |
| EP2686344A1 (en) | 2011-03-16 | 2014-01-22 | Protaffin Biotechnologie AG | Fgfr1-based antagonists with improved glycosaminoglycan affinity and methods of using same |
| WO2013007704A2 (en) | 2011-07-08 | 2013-01-17 | Protaffin Biotechnologie Ag | Novel sdf-1-based glycosaminoglycan antagonist and methods of using same |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000507596A (ja) * | 1996-04-02 | 2000-06-20 | プロジェニクス・ファーマスーティカルス・インコーポレーテッド | Ｃｄ４▲上＋▼細胞のｈｉｖ―１感染を防ぐ方法 |
| JP2003532683A (ja) * | 2000-05-09 | 2003-11-05 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 造血細胞のｃｘｃｒ４アンタゴニスト治療 |
| WO2005054285A1 (en) * | 2003-12-04 | 2005-06-16 | Protaffin Biotechnologie Ag | Gag binding proteins |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364894A (en) * | 1993-03-31 | 1994-11-15 | Tremco, Inc. | Emulsification of asphalt and modified asphalt with primary emulsifier polymers comprised of acrylic acid type monomers |
| WO2004094465A2 (en) * | 2003-04-23 | 2004-11-04 | The Board Of Trustees Of The University Of Illinois Office Of Technology Management University Of Illinois At Urbana-Champaign | Synthetic molecules that mimic chemokines |
| US7662221B2 (en) * | 2006-06-23 | 2010-02-16 | Johns Manville | Spray applied building wrap coating material, spray applied building wrap, and building construction assembly |
| AT504685B1 (de) * | 2006-12-20 | 2009-01-15 | Protaffin Biotechnologie Ag | Fusionsproteine |
-
2007
- 2007-10-24 EP EP07450189A patent/EP2053060A1/en not_active Withdrawn
-
2008
- 2008-10-23 CN CN200880113405A patent/CN101835800A/zh active Pending
- 2008-10-23 MX MX2010004025A patent/MX2010004025A/es not_active Application Discontinuation
- 2008-10-23 NZ NZ584278A patent/NZ584278A/en not_active IP Right Cessation
- 2008-10-23 WO PCT/EP2008/008960 patent/WO2009053064A1/en not_active Ceased
- 2008-10-23 BR BRPI0818009 patent/BRPI0818009A2/pt not_active IP Right Cessation
- 2008-10-23 CA CA2702502A patent/CA2702502A1/en not_active Abandoned
- 2008-10-23 KR KR1020107008264A patent/KR20100085041A/ko not_active Ceased
- 2008-10-23 AU AU2008315614A patent/AU2008315614A1/en not_active Abandoned
- 2008-10-23 EP EP08842736A patent/EP2203473A1/en not_active Withdrawn
- 2008-10-23 JP JP2010530341A patent/JP2011501675A/ja active Pending
- 2008-10-23 EA EA201000688A patent/EA201000688A1/ru unknown
- 2008-10-23 US US12/738,976 patent/US20100298203A1/en not_active Abandoned
-
2010
- 2010-04-22 IL IL205300A patent/IL205300A0/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000507596A (ja) * | 1996-04-02 | 2000-06-20 | プロジェニクス・ファーマスーティカルス・インコーポレーテッド | Ｃｄ４▲上＋▼細胞のｈｉｖ―１感染を防ぐ方法 |
| JP2003532683A (ja) * | 2000-05-09 | 2003-11-05 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 造血細胞のｃｘｃｒ４アンタゴニスト治療 |
| WO2005054285A1 (en) * | 2003-12-04 | 2005-06-16 | Protaffin Biotechnologie Ag | Gag binding proteins |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009053064A8 (en) | 2009-07-16 |
| CN101835800A (zh) | 2010-09-15 |
| BRPI0818009A2 (pt) | 2015-04-14 |
| IL205300A0 (en) | 2010-12-30 |
| MX2010004025A (es) | 2010-04-30 |
| EP2053060A1 (en) | 2009-04-29 |
| NZ584278A (en) | 2012-06-29 |
| EA201000688A1 (ru) | 2010-10-29 |
| US20100298203A1 (en) | 2010-11-25 |
| AU2008315614A1 (en) | 2009-04-30 |
| CA2702502A1 (en) | 2009-04-30 |
| EP2203473A1 (en) | 2010-07-07 |
| WO2009053064A1 (en) | 2009-04-30 |
| KR20100085041A (ko) | 2010-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101278459B1 (ko) | Ｇａｇ 결합 단백질 | |
| CN101790537A (zh) | 拮抗糖胺聚糖的mcp-1突变体及其用途 | |
| US7425324B2 (en) | Antagonists of MCP proteins | |
| EP1515990B1 (en) | Antagonists of cxcr3-binding cxc chemokines | |
| KR20070008510A (ko) | 케모킨 변이체의 치료적 용도 | |
| JP2011501675A (ja) | Ｓｄｆ−１を基礎としたグリコサミノグリカンアンタゴニスト、及びその使用方法 | |
| AU2002358144B2 (en) | Chemokine mutants acting as chemokine antagonists | |
| PL204231B1 (pl) | Zastosowanie mutanta chemokiny CC, kompozycja farmaceutyczna do leczenia stwardnienia rozsianego, skrócona i zmutowana ludzka RANTES i sposób jej wytwarzania, cząsteczka DNA i zawierający ją wektor ekspresyjny oraz komórka gospodarza | |
| US20070160574A1 (en) | Design of CXC chemokine analogs for the treatment of human diseases | |
| JPH05271291A (ja) | 機能性ポリペプチド | |
| EP1673388B1 (en) | Cxcl8 antagonists | |
| US12098175B2 (en) | Peptide inhibitors targeting the CXCL12/HMGB1 interaction and uses thereof | |
| EP2729487A2 (en) | Novel sdf-1-based glycosaminoglycan antagonist and methods of using same | |
| JPWO2012005313A1 (ja) | 環状ペプチド化合物またはその薬理的に許容される塩およびその製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101228 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110829 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130319 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130523 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130530 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20130919 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140310 |